Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Chinese Pediatric Subjects With Relapsed or Refractory B Precursor Acute Lymphoblastic Leukemia
NCT06054113Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by Amgen. Primary endpoints: Complete Remission at 84 days and Complete Remission with Partial Recovery of Peripheral Blood Counts at 84 days. Started Jul 2024; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06054113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054113.